Skip to content
MarketScale
‹ Back to IndustriesHealthcare

As Omicron Variant Spreads, At-Home Tests May Not Be Home for the Holidays

Omicron is the word on everyone’s tongues this holiday season, as the latest COVID-19 variant is surging just as the country enters peak travel dates. Already, airports have seen the most traffic since before the pandemic. The Biden administration has implemented testing requirements, regardless of vaccination status, to all international travelers to help curb the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Omicron is the word on everyone’s tongues this holiday season, as the latest COVID-19 variant is surging just as the country enters peak travel dates. Already, airports have seen the most traffic since before the pandemic. The Biden administration has implemented testing requirements, regardless of vaccination status, to all international travelers to help curb the spread. At-home tests have fast become a popular way for people to check their COVID-status, and the industry is having to adjust quickly as variants develop.

According to Gerald Commissiong, the Chief Executive Officer of Todos Medical, some at-home tests have already been rendered ineffective as the already-existent variants have changed the sequences in the virus.

“We need to start thinking about a completely new set of tests that are able to detect different parts of the virus that do not mutate,” said Commissiong.

Todos Medical is working on their own 3CL protease test that wouldn’t rely on the ever-changing sequence of the virus to detect it.

“That may be a solution to get around a mutating virus,” he said.

Another challenge during the holiday season regarding at-home tests is the delayed delivery times for packages, which could render a test potentially useless if the tested individual later encountered someone with the virus, or if the integrity of the test degraded during the shipping process. He says increasing the number of local labs is a workaround for this situation to help lessen delivery time. Commissiong spoke highly of the vaccines, though stressed that they are designed to prevent hospitalization and death.

“If you get sick, you’re less likely to have a severe disease and potentially less likely to get long COVID,” said Commissiong.

He called this “a call to action,” considering many people who have had the virus have dealt with extended issues tasting, smelling, brain fog and even worse symptoms. Commissiong spoke of the necessity to develop a strategy in how to implement rapid tests. Without such a strategy in place, he recommends the PCR test for the holiday,

“The PCR test is really the best test if you are going to go and see people and are worried you could be carrying the disease,” said Commissiong.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Sentara put a predictive model in Epic’s worklist

Sentara put a predictive model in Epic’s worklist

Sentara Health embedded a predictive risk model into Epic and redesigned nursing workflows, reducing hospital-onset MRSA bacteremia by about 45%, according to Healthcare IT News. Healthcare IT News also reported that DaVita’s CIO said embedding AI-powered insights into clinical workflows, not simply collecting more data, is helping clinicians coordinate care. Together, the examples point to ROI when insights are placed in clinical workflows.

  • 01According to Healthcare IT News, Sentara reduced hospital-onset MRSA bacteremia by about 45% after embedding a predictive risk model into Epic and redesigning nursing workflows.
  • 02More than half (56%) of respondents cited software and technology as one of their top three strategic priorities, and around 75% expected spending growth to continue over the next 12 months.

Sep 11, 2026

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS Sets $90-$420 Per-Patient Payments for Chronic Care Tech

CMS's ACCESS payment model, fully active as of July 2026, pays companies $90 to $420 per Medicare beneficiary per year for technology-supported chronic care tied to outcomes, according to HFMA. The model also requires participants to connect through CMS-designated interoperability networks, and more tech companies than traditional providers have signed on so far.

  • 01CMS ACCESS model provides annual payments of $90 to $420 per Medicare beneficiary for chronic care supported by technology.
  • 02Payments in the ACCESS model range from $90 to $420 per beneficiary per year depending on whether specified outcome targets are met.
  • 03The initiative aims to promote the integration of technology in chronic care management.

Sep 10, 2026

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

Google’s AlphaGenome Atlas puts billions of DNA variants in reach

AlphaGenome Atlas gives researchers predicted molecular effects for possible DNA changes across the human genome, helping teams prioritize variants for experimental follow-up.

  • 01The Atlas covers roughly nine billion possible single-letter DNA substitutions, according to The Verge.
  • 02Predictions can prioritize research questions but do not establish clinical findings.
  • 03The useful implementation pattern is prediction, study-specific evidence, then validation.

Sep 9, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512